Category: Vasculitis

In a pivotal 2021 clinical trial (ADVOCATE), avacopan was shown to be noninferior to prednisone taper for achieving remission in ANCA-associated vasculitis at 26 weeks and superior for sustained remission at 52 weeks. This groundbreaking medication offers a targeted treatment approach, allowing for a significant reduction in glucocorticoid exposure.

Prompt treatment for giant cell arteritis (GCA) is crucial to prevent vision loss, a complication that affects up to 20% of untreated patients. This necessity makes understanding **what is the drug of choice for giant cell arteritis?** a critical question for patients and clinicians alike.

In a pivotal clinical trial, 65.7% of participants treated with Tavneos achieved sustained remission of ANCA-associated vasculitis symptoms at 52 weeks, a significantly higher rate than the standard treatment arm. For adults managing severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), understanding what are the benefits of taking Tavneos is crucial for considering this targeted therapy.

Antihistamines are sometimes used as a symptomatic treatment for specific, skin-limited types of vasculitis, such as urticarial vasculitis. However, their effectiveness is limited, as they do not address the underlying inflammation of the blood vessels, which requires more potent therapies.

Drug-induced vasculitis accounts for approximately 3% of all vasculitis cases [1.2.1]. This condition involves inflammation of blood vessels triggered by certain medications. Understanding **which drugs cause vasculitis** is the first step toward diagnosis and management.